Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 589.2 DKK -20.72% Market Closed
Market Cap: 2.6T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Novo Nordisk A/S
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novo Nordisk A/S
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Total Equity
kr120.5B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
12%
H Lundbeck A/S
CSE:HLUN A
Total Equity
kr22B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Total Equity
kr4.4B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Total Equity
kr25.8m
CAGR 3-Years
-21%
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

Market Cap
2.6T DKK
Industry
Pharmaceuticals
Economic Moat
Wide

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Novo Nordisk A/S's Total Equity?
Total Equity
120.5B DKK

Based on the financial report for Sep 30, 2024, Novo Nordisk A/S's Total Equity amounts to 120.5B DKK.

What is Novo Nordisk A/S's Total Equity growth rate?
Total Equity CAGR 10Y
12%

Over the last year, the Total Equity growth was 30%. The average annual Total Equity growth rates for Novo Nordisk A/S have been 22% over the past three years , 18% over the past five years , and 12% over the past ten years .

Back to Top